Completed PHASE1 INTERVENTIONAL 1-arm NCT05712265

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

A Phase 1, Open-Label, Fixed-Sequence Crossover Study to Evaluate the Effect of a Strong Inhibitor of Cytochrome P450 2C19 on the Pharmacokinetics of Miricorilant in Healthy Subjects

Sponsor: Corcept Therapeutics

Conditions Antipsychotic Induced Weight Gain Non-alcoholic Steatohepatitis (NASH)

Interventions Fluvoxamine Miricorilant

Updated 4 times since 2023 Last updated: Mar 20, 2023 Started: Jan 24, 2023 Primary completion: Feb 23, 2023 Completion: Feb 23, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Antipsychotic Induced Weight Gain and Non-alcoholic Steatohepatitis (NASH), this trial is completed. The trial is conducted by Corcept Therapeutics and has accumulated 4 data snapshots since 2023. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Apr 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE1

First recorded

Jan 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Corcept Therapeutics

Data source: Corcept Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States